SCHEMBL1663174

SCHEMBL1663174

O=C(CNC(=O)c1ccc(-c2ccc(C(=O)NCC(=O)Nc3ccc(N4CCOCC4)cc3)cc2)cc1)Nc1ccc(N2CCOCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
POLB P06746 2/20 0.63
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
MAPT P10636 8/20 0.60
ATM Q13315 1/20 0.60
NPC1 O15118 1/20 0.60
TP53 P04637 1/20 0.60
PKM P14618 1/20 0.60
MAPK1 P28482 1/20 0.60
RAB9A P51151 1/20 0.60
LMNA P02545 2/20 0.57
ALDH1A1 P00352 4/20 0.56
CSNK1D P48730 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
KDM1A O60341 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
KDM1B Q8NB78 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769939 0.95 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1POLBHDAC8HDAC6
SCHEMBL1663046 0.94 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1POLBHDAC8HDAC6
SCHEMBL1665580 0.87 SMN1; SMN2 (0.64) SMN1; SMN2L3MBTL1POLBHDAC8HDAC6
SCHEMBL2350884 0.82 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1MAPTATMNPC1
SCHEMBL1662743 0.78 HDAC8 (0.68) SMN1; SMN2HDAC8HDAC6MAPTATM
SCHEMBL1663783 0.77 HDAC8 (0.81) SMN1; SMN2L3MBTL1HDAC8HDAC6MAPT
SCHEMBL8770431 0.77 HDAC8 (0.81) SMN1; SMN2L3MBTL1HDAC8HDAC6MAPT
SCHEMBL1109299 0.76 ALDH1A1 (0.52) SMN1; SMN2L3MBTL1POLBHDAC8HDAC6
SCHEMBL22811216 0.76 HDAC8 (0.58) POLBHDAC8HDAC6MAPTATM
SCHEMBL24499473 0.76 MAPT (0.68) SMN1; SMN2POLBMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL SMN1; SMN2 3850/4885L3MBTL1 2414/4885POLB 3018/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF SMN1; SMN2 941/4885L3MBTL1 765/4885POLB 3224/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF SMN1; SMN2 941/4885L3MBTL1 765/4885POLB 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.